Skip to main content

Table 2 Dose cohort and escalation increment

From: A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

Dose level (cohort) Daily dose of PHI-101 (once daily) Escalation increment from the previous dose
-1 20 mg 1 tab. - 20 mg - 50%
1 (starting dose) 40 mg 2 tab. - -
2 80 mg 4 tab. 40 mg 100%
3 120 mg 6 tab. 40 mg 50%
4 160 mg 8 tab. 40 mg 33%
5 200 mg 10 tab. 40 mg 25%
6 (maximum planned dose) 240 mg 12 tab. 40 mg 20%